SCHEMBL7702992

SCHEMBL7702992

CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](C)[C]=O)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 2/20 0.53
GRIA1 P42261 1/20 0.47
CPA1 P15085 1/20 0.45
CPA2 P48052 1/20 0.45
CPA4 Q9UI42 1/20 0.45
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
BACE1 P56817 1/20 0.43
BACE2 Q9Y5Z0 1/20 0.43
OPRD1 P41143 1/20 0.42
CASP3 P42574 1/20 0.42
CASP7 P55210 1/20 0.42
CTSL P07711 1/20 0.41
REN P00797 1/20 0.41
FOLH1 Q04609 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14370014 0.85 CASP1 (0.60) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL2314756 0.84 CASP1 (0.61) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL2314769 0.84 CASP1 (0.61) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL646595 0.84 CASP1 (0.55) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL24310822 0.83 CASP1 (0.63) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL7752844 0.83 CASP1 (0.55) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL9559471 0.83 GRIA1 (0.50) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL5689768 0.82 CASP1 (0.59) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL8764076 0.81 CASP1 (0.54) CASP1GRIA1CPA1CPA2CPA4
SCHEMBL30031739 0.81 CASP1 (0.55) CASP1GRIA1CPA1CPA2CPA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6348570-B1 TETRAPEPTIDES; DIAGNOSING AND MONITORING INFLAMMATORY, NERVOUS SYSTEM, SKIN, CARDIOVASCULAR, RESPIRATORY SYSTEM, GASTROINTESTINAL, UROGENITAL AND IMMUNE DISORDERS; EVALUATING INHIBITORS MERCK & CO., INC. 2002-02-19 US disclosed